ABSTRACT The eicosanoid vasodilator prostacyclin (PGI 2 ) reduces resistance to pulmonary blood flow and attenuates pulmonary hypertension in mammals. However, sparse information is available regarding the responsiveness of the avian pulmonary vasculature to PGI 2 . Accordingly, in 3 experiments we evaluated the pulmonary vascular responses to PGI 2 in male broilers. In experiment 1, infusing PGI 2 (10 µg/min) into clinically healthy broilers did not reduce their pulmonary vascular resistance (PVR) but did reduce their pulmonary arterial pressure (PAP) by lowering their cardiac output. Within 4 min after stopping the PGI 2 infusion, the cardiac output and PAP returned to preinfusion levels. In experiment 2, the responses to PGI 2 were evaluated after arachidonic acid (AA) had been infused to preconstrict the pulmonary vasculature. The AA infusion (400 µg/min) consistently triggered dramatic, sustained pulmonary vasoconstriction (increased PVR) and pulmonary hypertension (increased PAP). Concurrent PGI 2 infusions did not reduce PVR but did reduce PAP by lowering cardiac output. Within 4 min after stopping the PGI 2 infusion, PAP and cardiac output returned to their previous (hypertensive)
INTRODUCTION
Appropriate inflammatory stimuli (e.g., bacterial lipopolysaccharide) and physical stimuli (e.g., membrane stretch, distortion, or shear stress) can cause leukocytes, platelets, and endothelial cells to express the enzyme phospholipase A 2 , which cleaves arachidonic acid (AA) from cell membrane phospholipids. Free AA then is converted by lipooxygenase into leukotrienes or by constitutive and inducible cyclooxygenases (COX-1 and COX-2, respectively) into prostaglandin H 2 (PGH 2 ), which in turn serves as a common intermediate for the synthesis of other eicosanoids (oxygenated metabolites of AA) such as thromboxane A 2 (TxA 2 ) and prostacyclin (PGI 2 ). Eicosanoids are not stored inside cells or tissues; therefore, 2005 Poultry Science Association, Inc. Received for publication August 19, 2004 . Accepted for publication October 29, 2004. 1 To whom correspondence should be addressed: rwideman@ uark.edu. 442 levels attributable to the ongoing AA infusion. In experiment 3, PGI 2 was infused (10 µg/min) into clinically healthy (PAP ≤ 24 mmHg) or subclinically hypertensive (PAP ≥ 27 mmHg) broilers. Throughout this experiment broilers in the hypertensive group had higher PAP values than broilers in the healthy group. The PGI 2 infusion reduced PAP in both groups but did not reduce PVR. Instead, the pulmonary hypotensive response to PGI 2 infusion was associated with a reduction in cardiac output in both groups. In all 3 experiments PGI 2 reduced PAP by reducing cardiac output rather than by reducing PVR. There was no evidence that PGI 2 acts as an effective pulmonary vasodilator in broilers regardless of whether their pulmonary vasculature was apparently normal (clinically healthy), had been pharmacologically preconstricted (AA infusion), or initially exhibited the vasoconstriction that is typical of the pathogenesis of pulmonary hypertension syndrome in broilers (PAP ≥ 27 mmHg). The consistent failure of PGI 2 to elicit pulmonary vasodilation in this study suggests fundamental differences in AA metabolism or the etiology of pulmonary hypertension may exist when broilers are compared with mammals. their rate of release directly reflects their rate of de novo synthesis, which in turn depends on the tissue-specific distribution and relative activities of key enzymes. For example platelets and macrophages primarily express the enzyme thromboxane synthase, which rapidly converts PGH 2 to TxA 2 . In contrast, endothelial cells lining blood vessels primarily express the enzyme prostaglandin I synthase; consequently, the predominant eicosanoid produced by vascular tissues is PGI 2 . In most mammalian species TxA 2 promotes platelet aggregation and causes systemic and pulmonary vasoconstriction, whereas PGI 2 inhibits platelet aggregation and causes systemic and pulmonary vasodilation (Hyman et al., 1978; Menconi et al., 1984; Tod et al., 1992; Chilton et al., 1997; Robbins et al., 2001; Heller et al., 2003) .
The results of studies focused specifically on pulmonary vascular responses to TxA 2 and PGI 2 support the hypothesis that TxA 2 is a primary mediator of pathological increases in pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP; pulmonary hypertension). Conversely, vasodilation mediated by PGI 2 reduces resistance to blood flow through the lungs and, thereby, opposes the development of pulmonary hypertension. Mammalian pulmonary endothelial cells normally synthesize PGI 2 continuously to maintain a relatively relaxed (dilated) vascular tone; however, in several studies i.v. infusions of PGI 2 failed to cause pulmonary vasodilation unless the vasculature had been pharmacologically preconstricted or unless a preexisting state of pulmonary hypertension had developed (Hyman et al., 1978; Cassin, 1987; Christman et al., 1992; Ibe and Raj, 1992; Tod et al., 1992; Christman, 1998) . For example, human patients diagnosed with primary pulmonary hypertension may exhibit widely varying responses to i.v. infusions of exogenous PGI 2 (Epoprostenol, a stable PGI 2 derivative), but a patient's prognosis for survival is greatest when an acute i.v. infusion of Epoprostenol causes a >50% reduction in their PVR (Raffy et al., 1996; Robbins et al., 1998a) .
Modern broiler chickens have a pulmonary vascular capacity that is only marginally adequate to accommodate the cardiac output required to support the metabolic demands incurred by fast growth and the extremes of environmental temperatures. Accordingly, broilers are susceptible to the onset of pulmonary hypertension leading to pulmonary hypertension syndrome (PHS, ascites) whenever their right ventricle must develop elevated PAP to propel cardiac output through lungs with inadequate pulmonary vascular capacity as characterized by elevated PVR (Wideman and Bottje, 1993) . Vasoconstrictors increase PVR and theoretically can initiate or accelerate the pathogenesis of PHS by forcing the right ventricle to further increase PAP. Vasodilators reduce PVR and delay the onset of pulmonary hypertension and PHS (Wideman, 2000 (Wideman, , 2001 Xiang et al., 2004) . Within this context, sparse information is available regarding the responsiveness of the avian pulmonary vasculature to PGI 2 .
Accordingly, in the present study we evaluated pulmonary vascular responses to PGI 2 in broilers having normal (≤24 mmHg) or subclinically hypertensive (≥27 mmHg) PAP. The responses to PGI 2 also were evaluated in broilers in which adenosine 5′-diphosphate (ADP) or AA had been infused to preconstrict the pulmonary vasculature. In several mammalian species, ADP infusions stimulated platelets to release the vasoconstrictors TxA 2 and serotonin. These infusions also caused platelets to form aggregates (microemboli) large enough to physically occlude the microvasculature (Mustard and Packham, 1970; Hyman et al., 1971 Hyman et al., , 1978 . Serotonin is released and TxA 2 is synthesized by activated avian thrombocytes, and both are known to trigger pulmonary vasoconstriction and pulmonary hypertension in broilers (Wideman et al., 1998a Chapman and Wideman, 2002) . However, previous studies have indicated that exogenous ADP does not cause the nucleated thrombocytes of nonmammalian vertebrates to form aggregates (Belamarich et al., 1966 (Belamarich et al., , 1968 . Intravenous AA infusions also can trigger mammalian platelet aggregation, leading to the release of TxA 2 and serotonin, and the formation of microemboli. In addition, infused AA crosses cell membranes and bypasses the rate-limiting phospholipase A 2 -mediated step in the eicosanoid cascade, thereby directly providing the substrate for the synthesis of PGH 2 by cyclooxygenases. The pulmonary hypertensive response to AA infusions can be mimicked by infusing prostaglandin G 2 or PGH 2 and has been attributed to increased synthesis of TxA 2 (Hyman et al., 1978; Cassin, 1987; Tod et al., 1992) .
MATERIALS AND METHODS

Experiment 1
Male broilers from a commercial hatchery 2 were transported on the day of hatch to the Poultry Environmental Research Laboratory at the University of Arkansas Poultry Research Farm, where they were wing-banded and placed on fresh wood shavings litter in an environmental chamber (8 m 2 floor space). Chicks were brooded at 33°C from d 1 to 5, 29°C from d 6 to 10, and 26°C thereafter. They were fed a 23% CP corn-soybean meal-based broiler ration formulated to meet NRC (1994) standards. Feed and water were provided ad libitum. Lights were on for 24 h/d through d 5 and for 12 h/d thereafter. At 50 to 56 d of age, 16 broilers (3,008 ± 51 g of BW, mean ± SEM) were prepared for surgery as described previously Chapman and Wideman, 2002) . All birds had full access to feed and water until they were anesthetized. A surgical plane of anesthesia was induced with intramuscular injections of allobarbital (5,5-diallylbarbituric acid; 3 16 mg/kg of BW) and ketamine HCl (45 mg/kg of BW). 4 The birds were fastened in dorsal recumbency on a surgical board thermostatically regulated to maintain a surface temperature of 30°C. An incision was made to open the thoracic inlet, and a Transonic ultrasonic flow probe 5 was positioned on the left pulmonary artery. The probe was connected to a Transonic T206 blood flow meter 5 to confirm signal acquisition and record blood flow through the pulmonary artery, and the skin of the thoracic inlet was sealed with surgical wound clips. Silastic tubing (0.012 in. i.d., 0.037 in. o.d.) 6 filled with heparinized saline (150 units of ammonium heparin/mL of 0.9% NaCl) 3 was inserted through the left basilica (wing) vein. The distal end of the cannula was attached to a blood pressure transducer interfaced through a Transbrige preamplifier 7 to a Biopac MP100 data acquisi-tion system using AcqKnowledge software. 8 The Silastic cannula was advanced into the right pulmonary artery by monitoring the characteristic pulse pressures to identify its location . PE-50 polyethylene tubing filled with heparinized saline was inserted into the left wing vein and was advanced to a position near the inferior vena cava for i.v. injections. In 10 birds, PE-50 tubing filled with heparinized saline was inserted into the brachial artery, and the distal end was attached to a blood pressure transducer to monitor the mean arterial pressure. After surgical preparations were complete and a stabilization period of 10 min had elapsed, control data were recorded for 15 min. All birds received a series of bolus i.v. injections of sterile diluent and PGI 2 dissolved in the diluent. The 10 birds with a systemic arterial cannula received a 10-min constant i.v. infusion of PGI 2 preceding or following the series of bolus injections. To prepare the PGI 2 , 0.5 mg of Flolan (epoprostenol sodium) 9 was dissolved in 10 mL of sterile diluent 9 (50 µg of PGI 2 /mL). The bolus injection series consisted of an initial 1 mL of the diluent alone (n = 16), followed by 5 (n = 16), 10 to 15 (n = 13), 20 to 25 (n = 13), or 40 to 250 (n = 5) µg of the PGI 2 . For each bolus the appropriate volume of PGI 2 (e.g., 0.1 mL for the 5 µg bolus) was drawn into a 1-mL tuberculin syringe, injected through a 23-gauge needle into the PE-50 wing vein cannula, and flushed into the bird with a 0.5-mL injection of diluent or 0.9% NaCl. Sufficient time elapsed after each injection (depending on the dose of PGI 2 ) to permit pulmonary and systemic arterial pressures to return to stable values before subsequent injections. The PAP data were averaged electronically during a 60-s interval prior to the injection (preinjection), when the pressure reached its lowest level within 3 min postinjection (minimum), and during the 60-s interval prior to the subsequent injection (postinjection). Initial differences in PAP were normalized using each bird's preinjection sample interval to calculate the percentage change for subsequent sample intervals. For the constant infusion studies, a syringe infusion pump 10 delivered PGI 2 at 10 µg/min (50 µg of PGI 2 /mL at 0.2 mL/min) for 10 min. Data were averaged electronically at 4, 2, and 0.5 min prior to the start of the infusion (control sample intervals C1, C2, C3), at 0.5, 2, 4, 6, 8, and 10 min after the PGI 2 infusion began (PGI 2 infusion sample intervals P0.5, P2, P4, P6, P8, and P10), and during a recovery period at 0.5, 2, 4, and 6 min after the infusion was stopped (recovery sample intervals R0.5, R2, R4, R6). Experiments were terminated by injecting birds i.v. with 10 mL of 0.1 M KCl.
Experiment 2
Male broilers were reared as described for experiment 1. At 33 d of age, pilot studies were conducted on 3 8 Biopac Systems, Inc., Santa Barbara, CA. broilers to assess pulmonary hypertensive responses to i.v. infusions of ADP 3 or AA. 11 The broilers were anesthetized and surgically prepared to record mean systemic arterial pressure, PAP, and blood flow through the left pulmonary artery as described for experiment 1. After surgical preparations were complete, the birds received constant i.v. infusions of ADP. The ADP (Sigma catalog no. A-2754, lot no. 073K707) was dissolved at 1,000 µg/ mL in 1.25% mannitol and was infused at rates ranging from 50 to 400 µg ADP/kg of BW per min based on reports that i.v. infusion rates of 50 to 200 µg ADP/kg of BW per min causes pulmonary hypertension in dogs (Hyman et al., 1971) . Intravenous infusions of AA (Cayman catalog no. 90010; stock AA dissolved at 100 mg of AA/mL in ethanol) also were evaluated. Prior to each experiment the stock AA was diluted to 1 or 2 mg/mL in 1.25% mannitol and was infused at rates ranging from 10 to 400 µg of AA/min. Based on these pilot studies, 11 birds (36 to 43 d of age, 2,206 + 65 g of BW, mean ± SEM) were surgically prepared, a 10-min stabilization period was allowed to elapse, and control data were recorded. Next AA was infused for 20 min at a rate of 400 µg/min. Approximately 6 min of AA infusion was required to preconstrict the pulmonary vasculature, as reflected by an increase in the PAP accompanied by little or no change in the cardiac output. The PGI 2 then was infused for 5 min at a rate of 10 µg/min (50 µg of PGI 2 /mL at 0.2 mL/min; prepared as described for experiment 1); 9 the ongoing AA infusion continued for an additional 10 min, and, after all infusions ceased, the final sample intervals were recorded during a 10-min recovery period before the experiments were terminated. Data were averaged electronically at 2-min intervals during the control period (control sample intervals C1, C2, C3), at 2-min intervals after the start of the AA infusion (AA infusion sample intervals A1 to A3), within 30 s before the start of PGI 2 infusion (AA infusion sample interval A4), at 1-min intervals beginning 120 s after the start of the PGI 2 infusion (PGI 2 infusion sample intervals AP1, AP2, AP3, AP4), when the lowest (minimum) PAP value was recorded (PGI 2 infusion sample interval APmin), at 2-min intervals after PGI 2 infusion ceased but with ongoing AA infusion (AA infusion sample intervals A5 to A8), and at 2-min intervals during the recovery period after all infusions had stopped (recovery sample intervals R1 to R4).
Experiment 3
At 43 to 53 d of age, 28 male broilers (2,860 ± 58 g of BW, mean ± SEM) were anesthetized and surgically prepared to record mean systemic arterial pressure, PAP, and blood flow through the left pulmonary artery as described for experiment 1. After surgical preparations were complete and a 10-min stabilization period had elapsed, control data were recorded for 5 min. Next, PGI 2 (Cayman catalog no. 18220, lot no. 19720n) 11 was diluted to 50 µg/ mL with sterile diluent 9 and was infused at a rate of 10 µg/min for 8 min. After the PGI 2 infusion ceased, data were recorded during a 10-min recovery period before FIGURE 1. Recording of the mean systemic arterial pressure (MAP), pulmonary arterial pressure (PAP), and blood flow through the left pulmonary artery (FLOW) for an individual male broiler in experiment 1 during the baseline data collection interval; during a constant i.v. infusion of prostacyclin (PGI 2 ) at 10 µg/min (PGI 2 from start to stop); after bolus injections of diluent and 5, 10, and 20 µg of PGI 2 ; and during a second constant infusion of PGI 2 (PGI 2 from start to stop). This broiler was the only one to receive more than one constant infusion of PGI 2 .
the experiments were terminated. Data were averaged electronically at 2-min intervals during the control period (control sample intervals C1 and C2), within 30 s before the start of PGI 2 infusion (control sample interval C3), at 2-min intervals beginning 30 s after the start of the PGI 2 infusion (PGI 2 infusion sample intervals P0.5, P2, P4, P6, P8), and at 2-min intervals beginning 30 s after the start of the recovery period (recovery sample intervals R0.5, R2, R4, R6). The PAP recorded during control sample intervals were used to divide the birds into groups representing the highest (30 ± 1 mmHg; range: 27 to 37 mmHg; n = 14) and lowest (20 ± 1 mmHg; range: 16 to 24 mmHg; n = 14) PAP cohorts.
Data Analysis
The protocol used for data averaging accommodates the influences of pulse pressure and respiratory cycles on pulmonary and systemic arterial pressures (Wideman et al., 1996) . The primary data recorded included PAP (mmHg), mean systemic arterial pressure (mmHg), and blood flow through the left pulmonary artery (mL/min). Heart rate (beats/min) was obtained by counting systolic peaks over time in the blood pressure recordings. Based on the assumption that cardiac output (mL/min) normally is divided approximately equally between the lungs, cardiac output was calculated as 2× blood flow through the left pulmonary artery. The cardiac output is the product of heart rate (beats/min) × stroke volume (mL/beat); consequently stroke volume was calculated as cardiac output divided by heart rate. Assuming the left and right atrial pressures remain close to zero, as assessed by direct cannulation (right atrium) or wedge pressure (left atrium) measurements , then the pressure gradient across the pulmonary circulation is essentially equal to PAP, and the pressure gradient across the systemic circulation is essentially equal to mean arterial pressure. Accordingly the relationship among pressure, flow, and resistance can be summarized by the following equations: PAP = cardiac output × PVR; mean arterial pressure = cardiac output × total peripheral resistance (Wideman et al., 1996) . Thus, PVR was calculated in relative resistance units as PAP divided by cardiac output, and total peripheral resistance was calculated as mean arterial pressure divided by cardiac output (Sturkie, 1986; Wideman et al., 1996) . Due to the strong correlation between cardiac output and body weight (Wideman, 1999) , the cardiac output and its derivative data (stroke volume, PVR, total peripheral resistance) were normalized per kilogram of BW on an individual bird basis. Responses to the different PGI 2 bolus injection dosages were compared within a sample interval using the SigmaStat One Way ANOVA procedure, and means were differentiated by Tukey's test. For the constant i.v. infusion studies, data were analyzed over time (across sample intervals) using the SigmaStat Repeated Measures ANOVA procedure, and means were differentiated by Dunnett's Method (Jandel Scientific, 1994) . In experiment 3, the differences between high and low PAP groups within a sample interval were compared using a t-test (Jandel Scientific, 1994) . The threshold for significance in all cases was P ≤ 0.05.
RESULTS
Experiment 1
The mean systemic arterial pressure, PAP, and blood flow through the left pulmonary artery for an individual FIGURE 2. Pulmonary arterial pressure (PAP, upper panel) and percentage change in PAP when compared with the preinjection value (lower panel) for male broilers in experiment 1 that received bolus injections of diluent (volume control, n = 16), followed by 5 (n = 16), 10 to 15 (n = 13), 20 to 25 (n = 13), or 40 to 250 (n = 5) µg of prostacyclin (PGI 2 ; mean ± SEM). Data were averaged electronically during a 60-s interval prior to the injection (Preinjection), when the PAP reached its lowest level within 3 min postinjection (Minimum) and during the 60-s interval prior to the subsequent injection (Postinjection). Asterisks (*) denote values that were lower than the preinjection value within an injection dosage (P ≤ 0.05).
a-d
Different letters indicate means that differed among injection dosages within a sample interval (P ≤ 0.05).
broiler are shown in Figure 1 . Infusion of PGI 2 at a rate of 10 µg/min reduced the mean systemic arterial pressure and PAP and reduced blood flow through the left pulmonary artery. All parameters returned to preinfusion levels within 5 min after the infusion ceased. The bolus injection of diluent had no effect, whereas bolus injections of 5, 10, and 20 µg PGI 2 elicited contemporaneous transient reductions in the mean systemic arterial pressure, PAP, and flow. Finally, a second infusion of PGI 2 elicited responses similar to those of the first infusion. The experiment shown in Figure 1 was the only instance in which more than one constant infusion of PGI 2 was adminis-FIGURE 3. Pulmonary arterial pressure (PAP, upper panel), pulmonary vascular resistance (PVR, middle panel), and cardiac output (CO, lower panel) for male broilers in experiment l (mean ± SEM; n = 10). Data were averaged electronically at 4, 2, and 0.5 min prior to the start of the infusion (control sample intervals C1, C2, C3); at 0.5, 2, 4, 6, 8, and 10 min after the prostacyclin (PGI 2 ) infusion began (PGI 2 infusion sample intervals P0.5, P2, P4, P6, P8, and P10); and during a recovery period at 0.5, 2, 4, and 6 min after the infusion was stopped (recovery sample intervals R0.5, R2, R4, R6). Asterisks (*) denote values that were lower than the C3 value (P ≤ 0.05).
tered; the remaining birds were infused once with PGI 2 , either preceding or following the series of bolus injections.
Pulmonary arterial pressure responses to bolus injections of PGI 2 are illustrated in Figure 2 . Even though preinfusion values did not differ (P = 0.177) among the different bolus injection dose ranges (Figure 2 , upper panel), the data were standardized based on percentage change from the preinjection values (Figure 2 , lower panel). On an absolute basis neither the diluent (volume control) nor 5 µg of PGI 2 injection reduced PAP, whereas all doses of PGI 2 greater than 5 µg reduced PAP when compared either with the respective preinjection values or with the minimum value for the volume control injection (Figure 2, upper panel) . A similar pattern was revealed for percentage change comparisons, with the addition that the response to 5 µg of PGI 2 attained significance ( Figure 2, lower panel) . Responses by other parameters such as the systemic arterial pressure and flow ( Figure  1) are not presented for the bolus injections because these parameters were evaluated in detail during the constant infusion of PGI 2 (below).
For all birds combined, none of the variables differed over time during control sample intervals C1 to C3 ( Figure  3 , Table 1 ). The constant infusion of PGI 2 caused a reduction in PAP (Figure 3, upper panel) that was not associated with pulmonary vasodilation (PVR was not reduced; Figure 3 , middle panel) but was associated with a reduction in cardiac output (Figure 3, lower panel) . The reduction in cardiac output must be attributed primarily to a reduction in stroke volume accompanied by a marginal decline in heart rate (P = 0.093) ( Table 1 ). The mean systemic arterial pressure declined dramatically during the PGI 2 infusion due to systemic vasodilation (reduction in total peripheral resistance), as well as to the reduction in cardiac output (Table 1, Figure 3 ). Within 4 min after stopping the PGI 2 infusion (sample interval R4), all variables returned to levels that did not differ from the respective preinfusion (sample intervals C1 to C3) values (Table 1, Figure 3 ).
Experiment 2
In pilot studies using 3 male broilers, infusion of ADP at ≥100 µg/kg of BW per min caused dramatic, dosedependent reductions in systemic arterial pressure (systemic hypotension) but failed to affect PAP (data not shown). Infusion of AA at 100 or 200 µg/min tended to cause a modest pulmonary hypertension (increased PAP) with a minimal impact on systemic arterial pressure, whereas infusion rates of 400 µg of AA/min consistently triggered dramatic, sustained pulmonary hypertension (data not shown). Based on these pilot observations, the 400 µg/min AA infusion rate was chosen for preconstricting the pulmonary vasculature. The responses of an individual broiler to AA and PGI 2 infusions are shown in Figure 4 . The AA infusion did not affect mean systemic arterial pressure or flow through the left pulmonary artery. However, AA infusion steadily increased PAP. The PGI 2 infusion was initiated and terminated midway through the ongoing AA infusion (start PGI 2 to stop PGI 2 ). Infusion of PGI 2 at 10 µg/min reduced the mean systemic arterial pressure and PAP and reduced blood flow through the left pulmonary artery. Within 5 min after the PGI 2 infusion ceased, systemic arterial pressure and blood flow returned to their initial baseline levels, whereas PAP returned to the elevated level caused by the ongoing infusion of AA. After stopping the AA infusion, the PAP declined below the level recorded at the beginning of the experiment.
For all birds combined, none of the variables differed over time during control sample intervals C1 to C3 ( Figure  5 , Table 2 ). Within 4 min after the start of AA infusion (sample interval A2) the PAP ( Figure 5, upper panel) and PVR ( Figure 5 , middle panel) increased when compared with the control sample intervals, whereas cardiac output was not significantly reduced ( Figure 5 , lower panel). The PGI 2 infusion reduced cardiac output (sample intervals AP1 to AP4) and PAP (sample intervals AP3 to AP4) but did not reduce PVR when compared with the C3 or A4 sample intervals. The reduction in cardiac output during PGI 2 infusion in experiment 2 can be attributed to reductions in heart rate and stroke volume ( Table 2 ). The mean systemic arterial pressure declined modestly when AA was infused alone and declined dramatically during the PGI 2 infusion due to systemic vasodilation (reduction in total peripheral resistance) coupled with a contemporaneous reduction in cardiac output (Table 2, Figure 5 ). Within 2 to 4 min after stopping PGI 2 infusion but with ongoing AA infusion (sample intervals A5 and A6), the PAP, cardiac output, heart rate, stroke volume, mean systemic arterial pressure, and total peripheral resistance returned to levels that did not differ from the respective values for these variables during sample interval A4 (prior to the start of PGI 2 infusion). After the AA infusion was stopped (sample intervals R3 to R4), the PAP, PVR, heart rate, and total peripheral resistance returned to levels that did not differ from the respective values for these variables during sample interval C3. Values for cardiac output, stroke volume, and mean systemic arterial pressure remained lower after stopping the AA infusion (sample intervals R3 to R4) than the respective initial control values (Table 2, Figure 5 ).
Experiment 3
The BW values for these 40-to 53-d-old male broilers averaged 2,781 ± 59 g and 2,949 + 57 g (mean + SEM; P = 0.051) in the high and low PAP groups, respectively. Within each group none of the variables differed over time during control sample intervals C1 to C3 (Figure 6 , Table 3 ). Throughout the experiment broilers in the high group had higher values for PAP than broilers in the low group ( Figure 6, upper panel) . The PGI 2 infusion reduced the PAP in both groups but did not reduce PVR ( Figure  6 , middle panel). Instead, the pulmonary hypotension in response to PGI 2 infusion was associated with a reduction in cardiac output in both groups (Figure 6, lower panel) . The reduction in cardiac output could be attributed to reductions in stroke volume and heart rate in both groups (Table 3 ). The mean systemic arterial pressure declined dramatically during the PGI 2 infusion due to reductions in total peripheral resistance and cardiac output in both groups (Table 3, Figure 6 ). Within 6 min after stopping the PGI 2 infusion (sample interval R6), all variables returned to levels that did not differ from the respective preinfusion (sample intervals C1 to C3) values (Table 3, Figure 6 ).
DISCUSSION
In all 3 experiments, intravenously administered PGI 2 successfully reduced the PAP. However, the pulmonary hypotensive responses to PGI 2 were not accompanied by , and cardiac output (CO, lower panel) for male broilers in experiment 2 (mean ± SEM; n = 11). Data were averaged electronically at 2-min intervals during the control period (control sample intervals C1, C2, C3), at 2-min intervals after the start of the arachidonic acid (AA) infusion (AA infusion sample intervals A1 to A3), within 30 s before the start of prostacyclin (PGI 2 ) infusion (AA infusion sample interval A4), at 1-min intervals beginning 120 s after the start of the PGI 2 infusion (PGI 2 infusion sample intervals AP1, AP2, AP3, AP4), at the point when the lowest (minimum) pulmonary arterial pressure value was recorded (PGI 2 infusion sample interval APmin), at 2-min intervals after PGI 2 infusion ceased but while AA infusion was ongoing (AA infusion sample intervals A5 to A8), and at 2-min intervals during the recovery period after all infusions had stopped (recovery sample intervals R1 to R4). Asterisks (*) denote means that differed (P ≤ 0.05) when compared with the C3 value. Plus symbols (+) denote means that differed (P ≤ 0.05) when compared with the A4 value.
reductions in PVR in clinically healthy broilers (experiment 1), in broilers in which the pulmonary vasculature had been pharmacological preconstriction by infusing AA (experiment 2), or in broilers exhibiting the primary pulmonary hypertension, pulmonary vasoconstriction, and elevated cardiac output that are characteristic of individuals developing PHS (experiment 3) (Wideman, 2000 (Wideman, , 2001 . Assuming that the pressure gradient across the pulmonary Values are means ± SEM for 11 broilers.
2 Sample intervals C1 to C3, A1 to A4, A5 to A8, and R1 to R4 were approximately 2 min apart; intervals AP1 to AP4 were approximately 1 min apart, beginning 120 s after the start of the PGI 2 infusion; Interval APmin was the minimum represents the time point when the lowest pulmonary arterial pressure was recorded. *Means within a row differed (P ≤ 0.05) from the C3 value by repeated measures ANOVA. †Means within a row were lower (P ≤ 0.05) when compared with the A4 value by repeated measures ANOVA FIGURE 6. Pulmonary arterial pressure (PAP, upper panel), pulmonary vascular resistance (PVR, middle panel), and cardiac output (CO, lower panel) for male broilers assigned to high (circles; ≥27 mmHg) and low (squares; ≤24 mmHg) PAP groups in experiment 3 (mean ± SEM; n = 14 per group). Data were averaged electronically at 4, 2, and 0.5 min prior to the start of the infusion (control sample intervals C1, C2, C3); at 0.5, 2, 4, 6, and 8 min after the prostacyclin (PGI 2 ) infusion began (PGI 2 infusion sample intervals P0.5, P2, P4, P6, and P8); and during a recovery period at 0.5, 2, 4, and 6 min after the infusion was stopped (recovery sample intervals R0.5, R2, R4, R6). Asterisks (*) denote values that were lower than the C3 value (P ≤ 0.05).
a,b
Means with different letters differ within a sample interval (P ≤ 0.05).
circulation is essentially equal to PAP , the magnitude of PAP is determined by multiplying PVR and cardiac output (Wideman and Bottje, 1993; Wideman, 2000) . Accordingly, if PAP declines while PVR remains constant, then pulmonary hypotension must be caused by a reduction in cardiac output. Indeed, PGI 2 reduced PAP solely by reducing cardiac output rather than by reducing PVR in all 3 experiments in the present study.
In mammals, PGI 2 and nitric oxide (NO) are recognized as 2 principle pulmonary vasodilators and intrapulmonary modulators of the detrimental effects of vasoconstrictors (Grabarevic et al., 1997; Christman, 1998 ; Robbins , 2001 Chen et al., 2001; Gryglewski et al., 2001; Nozik-Grayck et al., 2002) . In chickens NO clearly plays a protective role by dilating the pulmonary vasculature, attenuating the onset of pulmonary hypertension triggered by receptor-mediated endothelium-dependent vasoconstrictors, such as TxA 2 and lipopolysaccharide, and attenuating the pathophysiological progression leading to PHS (Wideman et al., 1995 (Wideman et al., , 1996 (Wideman et al., , 1998b Grabarevic et al., 1997; Martinez-Lemus et al., 1999 Ruiz-Feria et al., 2001; Villamor et al., 2002; Wang et al., 2002; Weidong et al., 2002; Odom et al., 2004) . In contrast, endothelium-dependent relaxation of chick pulmonary artery rings does not appear to depend on PGI 2 production in vitro (Villamor et al., 2002) , nor do intravenous PGI 2 infusions cause measurable dilation of the pulmonary vasculature in vivo (present study). The available evidence indicates that chicken lungs lack the capacity to respond to a key vasodilator of considerable importance in mammals (i.e., PGI 2 ). Therefore broilers must rely primarily on NO to modulate the onset of pulmonary hypertension.
Broilers are susceptible to the onset of pulmonary hypertension whenever the right ventricle must elevate PAP to propel cardiac output through lungs with inadequate pulmonary vascular capacity as characterized by elevated PVR. In this context, it is relevant that human patients with primary pulmonary hypertension are deemed to have the best prognosis for survival when short-term intravenous PGI 2 infusions reduce PVR sufficiently to also reduce PAP in spite of contemporaneous increases in cardiac output (Raffy et al., 1996; Robbins et al., 1998a) . In these highly responsive human patients, as well as in other mammals such as sheep, PGI 2 -mediated increases in cardiac output can be attributed to simultaneous increases in heart rate and stroke volume (cardiac output is the product of heart rate multiplied by stroke volume), which in turn reflect an increased rate of venous blood flow through the dilated pulmonary vasculature. Increased atrial and ventricular filling stimulate positive chronotropic (rate of contraction; Bainbridge reflex) and inotropic (force of contraction; Starling's law of the heart) cardiac responses (Robbins et al., 1998b; Cuiper et al., 1996) . In the present study intravenous infusions of PGI 2 triggered contemporaneous reductions in the stroke volume and heart rate of broilers. These negative inotropic and negative chronotropic responses to PGI 2 are consistent with a significant reduction in the return of venous blood to the heart. If PGI 2 dilates the systemic venules and large veins of broilers, the resulting increased pooling of blood within the venous volume reservoir would reduce venous return and, thus, atrial and ventricular filling, thereby causing simultaneous intrinsic reductions in heart rate and stroke volume (Sturkie, 1986) . Intravenously infused PGI 2 did consistently dilate systemic resistance vessels, and total peripheral resistance was reduced in all 3 experiments of the present study. However, changes in venous return and venous filling pressure were not assessed.
Assuming the pressure gradient across the systemic circulation is essentially equal to mean systemic arterial pressure, then the magnitude of mean arterial pressure must be determined by the product of total peripheral resistance multiplied by cardiac output. Intravenously infused PGI 2 dilates the systemic vasculature (reduces the total peripheral resistance) and causes consistent reductions in mean systemic arterial pressure in mammals (Robbins et al., 1998b; Cuiper et al., 1996) and broilers (present study). Evidently, the infused PGI 2 was not inactivated as it transited the broilers' lungs; rather, it persisted long enough to elicit systemic vasodilation. The rather dramatic impact of PGI 2 on mean systemic arterial pressure of broilers reflects contemporaneous reductions in total peripheral resistance and cardiac output.
Intravenous infusions of AA typically dilate the systemic vasculature and cause systemic hypotension (reduced mean systemic arterial pressure) and simultaneously trigger pulmonary hypertension in mammals (Hyman et al., 1978; Cassin, 1987; Tod et al., 1992) . These opposing responses by the separate vascular beds have been attributed to differences in the persistence (half-life) of the eicosanoid products of AA. The primary eicosanoid produced during intravenous AA infusion is TxA 2 , which is carried in the venous blood to the lungs, where it elicits pulmonary vasoconstriction. However, TxA 2 is rapidly inactivated as it transits the pulmonary vasculature, and therefore it does not persist in the blood long enough to constrict the systemic vasculature. The pulmonary vascular endothelium converts residual AA into PGI 2 , which is not rapidly metabolized by the lungs and, therefore, persists long enough to dilate the systemic vasculature in mammals (Hyman et al., 1978; Cassin, 1987; Christman et al., 1992; Tod et al., 1992; Cuiper et al., 1996) . Previous studies demonstrated the capacity of potent TxA 2 analogs to constrict the pulmonary and systemic vasculature of broilers , and the present study clearly establishes that AA infusions trigger pulmonary vasoconstriction consistent with the production of endogenous TxA 2 . However, AA infusion failed to elicit a profound vasodilation or hypotension within the systemic circulation. This result suggested that essentially all of the infused AA was rapidly converted into TxA 2 that then was inactivated within the lungs or that the lungs of broilers normally do not synthesize biologically active levels of PGI 2 (e.g., prostaglandin I synthase may be minimally expressed in the pulmonary vascular endothelium). Clarification of these issues must await measurements of plasma eicosanoid levels and prostaglandin synthase activities in future studies.
In summary, human patients with primary pulmonary hypertension have the best prognosis for survival when short-term infusions of PGI 2 elicit large reductions in the PVR accompanied by increases in cardiac output. All current evidence indicates that PGI 2 does not function as an effective vasodilator within the pulmonary vasculature of broilers, and PGI 2 infusions reduced rather than increased the cardiac output. The functional inefficacy of this key vasodilator may contribute to the onset of pulmonary hypertension in broilers that have a marginal pulmonary vascular capacity. Hemodynamic evaluations of broilers have confirmed that their pulmonary blood vessels have a low compliance (are poorly distensible), the vascular channels function as if they are fully engorged with blood (additional vascular volume cannot be recruited), and the precapillary arterioles are the primary sites of excessive resistance to pulmonary blood flow (Wideman, 2000 (Wideman, , 2001 Chapman and Wideman, 2001) . In view of substantial evidence that NO does serve as an important vasodilator in broiler lungs, perhaps an additional dilatory impact of PGI 2 should not be expected within a vascular bed that constantly is on the verge of being overwhelmed by the steady increments in cardiac output needed to sustain rapid growth (Wideman, 1999) . The current study clearly demonstrates that the PAP of broilers can be directly affected by changes in cardiac output in the absence of significant changes in PVR. The consistent failure of PGI 2 to elicit pulmonary vasodilation in this study suggests fundamental differences in AA metabolism or that the etiology of pulmonary hypertension may exist when broilers are compared with mammals.
